HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Swiss flavors and fragrances supplier is grouping Fragrances and Sensory Ingredients under a new division, to be headed by Global President Fragrances Achim Daub, firm announces May 8. Initiative, part of larger restructuring efforts at the company, "will offer the complete value chain from aroma chemicals, fragrance compositions, and cosmetic ingredients," Symrise notes. Daub joined the company last fall to oversee the realignment of the firm's fragrance division (1"The Rose Sheet" Nov. 21, 2005, p. 9)...

You may also be interested in...


Dr. Klaus Stanzl has been appointed president Scent & Care North America, in addition to his current position as global president Cosmetic Ingredients, fragrance supplier reports. Effective early June, Stanzl is responsible for "the further development of the fragrances, cosmetic ingredients, aroma chemicals and oral care business in the North American region," firm notes. The Scent & Care division was recently established through a merger of Symrise's former Fragrances and Sensory Ingredients divisions, headed by Global President Fragrances Achim Daub (1"The Rose Sheet" May 15, 2006, In Brief)...

Symrise’s Daub Appointed Global President Of Fragrance Division

Symrise exec Achim Daub will "ensure continuity" during the ongoing realignment of the company's Fragrance Division in his new position as global president of the unit, the firm announced Nov. 14. Effective immediately, Daub succeeds Tim Schaffner, who is retiring, Symrise said

Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts